The broader stock market faced renewed selling pressure today, with major indices experiencing sharp declines. The Dow Jones Industrial Average plunged 500 points, extending its recent losing streak as...
Investors prefer to invest in businesses that reap profits on a regular basis. To gauge the extent of profits, there is no better metric than net profit margin.A higher net margin reflects a company’s...
For Immediate ReleaseChicago, IL – December 26, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...
The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due...
Frank L Jr Jaksch, a director at $CDXC ($CDXC), sold 37,161 shares of the company on 12-13-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 13.2% of their...
Ozan Pamir, the Chief Financial Officer of $CDXC ($CDXC), bought 2,907 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...
U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss...
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results.